²ÝÁñ2024еس¶Ò»¶þ

Climate change is impacting both environmental and human health, and as a healthcare company with a global presence, we must do our part to address climate change head-on. Our areas of focus have been protecting and enabling stable access to water, helping protect public water resources and maintaining operations during extreme weather events.

²ÝÁñ2024еس¶Ò»¶þis committed to providing transparent information on our efforts to mitigate climate change, including our greenhouse gas emissions and energy management programs and performance, and we report regularly on our progress toward our goals.

We have reported on our climate program since 2017 to the CDP, a global nonprofit disclosure system for environmental issues. For more details on our climate change and water security programs please see our survey responses below.

We are working to reduce carbon emissions across our supply chain. We work across all three of our freight transportation modes - road, ocean and air - to that end. Supply reliability and transport efficiency are primary objectives. We focus on full truck loads and double stacking of pallets where possible and partner with our freight partners to move from dedicated containers to sharing capacity with other companies to better utilize space across the industry. Full truck loads are considered the most efficient mode of transit.

In 2024, ²ÝÁñ2024еس¶Ò»¶þsignificantly focused on Mode of Transport (MOT) for intercompany shipments and deliveries to our customers and piloted a new approach at our Distribution Center in Europe. As a result, we achieved 57% of shipments by air and 43% by sea freight, marking an increase of more than 300% by sea over the previous year. Looking ahead to 2025, we plan to extend this MOT model to other ²ÝÁñ2024еس¶Ò»¶þsites globally. Our goal is to continue transitioning from air freight to sea freight wherever feasible throughout the year.

As Viatris, we are compliant with the AMRIA Antibiotic Manufacturing Standard for our own operations and committed to implementing it across our external supply chain. All applicable ²ÝÁñ2024еس¶Ò»¶þmanufacturing locations with antibiotic production have been internally assessed and adhere to the AMRIA Antibiotic Manufacturing Standard, including meeting the PNEC (RQ<1) as calculated by mass balance.

Milestone Certification for Reducing the Risk of AMR in Manufacturing

²ÝÁñ2024еس¶Ò»¶þhas earned three BSI Kitemark Certifications under the AMRIA Manufacturing Standard – for two products at its Aurangabad, India, site and one product at its Troisdorf, Germany, manufacturing facility. The Antibiotic Manufacturing Standard, published by AMRIA and facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment. These certifications provide independent, third-party assurance and demonstrate that antibiotic residue emissions from solid and liquid waste streams are effectively controlled during manufacturing.